TW202003539A - 做為抗癌劑之環二核苷酸 - Google Patents
做為抗癌劑之環二核苷酸 Download PDFInfo
- Publication number
- TW202003539A TW202003539A TW108104810A TW108104810A TW202003539A TW 202003539 A TW202003539 A TW 202003539A TW 108104810 A TW108104810 A TW 108104810A TW 108104810 A TW108104810 A TW 108104810A TW 202003539 A TW202003539 A TW 202003539A
- Authority
- TW
- Taiwan
- Prior art keywords
- coor
- alkyl
- halogen
- substituted
- cycloalkyl
- Prior art date
Links
- 0 C*(*(C(C)=C(*=*)C(C)=*1)C1=*)=* Chemical compound C*(*(C(C)=C(*=*)C(C)=*1)C1=*)=* 0.000 description 51
- PYAQURYCLBJICV-YSRSKLTQSA-N Nc1c2nc[n]([C@@H]([C@@H]3F)O[C@H](COP(OC[C@H](C(C4)CO5)[C@@H]4[n]4c6nc7ncc[n]7c(O)c6nc4)(S)=O)[C@H]3OP5(S)=O)c2ncn1 Chemical compound Nc1c2nc[n]([C@@H]([C@@H]3F)O[C@H](COP(OC[C@H](C(C4)CO5)[C@@H]4[n]4c6nc7ncc[n]7c(O)c6nc4)(S)=O)[C@H]3OP5(S)=O)c2ncn1 PYAQURYCLBJICV-YSRSKLTQSA-N 0.000 description 1
- PYAQURYCLBJICV-RTQDPHFHSA-N Nc1c2nc[n]([C@@H]([C@@H]3F)O[C@H](COP(OC[C@H]([C@H](C4)CO5)[C@@H]4[n]4c6nc7ncc[n]7c(O)c6nc4)(S)=O)[C@H]3OP5(S)=O)c2ncn1 Chemical compound Nc1c2nc[n]([C@@H]([C@@H]3F)O[C@H](COP(OC[C@H]([C@H](C4)CO5)[C@@H]4[n]4c6nc7ncc[n]7c(O)c6nc4)(S)=O)[C@H]3OP5(S)=O)c2ncn1 PYAQURYCLBJICV-RTQDPHFHSA-N 0.000 description 1
- YWSWKUNUPHHETF-DIJHLZONSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(OC[C@H]([C@H](C2)CO3)[C@@H]2[n]2c(N=CNC4=O)c4nc2)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(OC[C@H]([C@H](C2)CO3)[C@@H]2[n]2c(N=CNC4=O)c4nc2)(S)=O)[C@H]1OP3(S)=O YWSWKUNUPHHETF-DIJHLZONSA-N 0.000 description 1
- JLXBJZOUHNLCPV-NVQRDWNXSA-N [O-][N+](c1ccc(CCN(C=CN2C3=O)C2=Nc2c3nc[n]2[C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)cc1)=O Chemical compound [O-][N+](c1ccc(CCN(C=CN2C3=O)C2=Nc2c3nc[n]2[C@@H]([C@@H]2O)O[C@H](CO)[C@H]2O)cc1)=O JLXBJZOUHNLCPV-NVQRDWNXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629956P | 2018-02-13 | 2018-02-13 | |
| US62/629,956 | 2018-02-13 | ||
| US16/272,172 US10519187B2 (en) | 2018-02-13 | 2019-02-11 | Cyclic dinucleotides as anticancer agents |
| US16/272,172 | 2019-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202003539A true TW202003539A (zh) | 2020-01-16 |
Family
ID=67542132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108104810A TW202003539A (zh) | 2018-02-13 | 2019-02-13 | 做為抗癌劑之環二核苷酸 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10519187B2 (enExample) |
| EP (1) | EP3752516B1 (enExample) |
| JP (1) | JP7296405B2 (enExample) |
| KR (1) | KR102950614B1 (enExample) |
| CN (1) | CN111902420B (enExample) |
| AR (1) | AR114369A1 (enExample) |
| CY (1) | CY1125159T1 (enExample) |
| DK (1) | DK3752516T3 (enExample) |
| ES (1) | ES2909616T3 (enExample) |
| HR (1) | HRP20220520T1 (enExample) |
| HU (1) | HUE058662T2 (enExample) |
| LT (1) | LT3752516T (enExample) |
| PL (1) | PL3752516T3 (enExample) |
| PT (1) | PT3752516T (enExample) |
| RS (1) | RS63128B1 (enExample) |
| SI (1) | SI3752516T1 (enExample) |
| SM (1) | SMT202200168T1 (enExample) |
| TW (1) | TW202003539A (enExample) |
| WO (1) | WO2019160884A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| MX2022008123A (es) | 2020-01-16 | 2022-07-21 | Bristol Myers Squibb Co | Reactivos y su uso para modular la sintesis enantiodivergente de enlaces c-p. |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| CN110234403A (zh) * | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| JP7186764B2 (ja) * | 2017-07-28 | 2022-12-09 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| JP7208225B2 (ja) * | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| KR102812783B1 (ko) | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
-
2019
- 2019-02-11 US US16/272,172 patent/US10519187B2/en active Active
- 2019-02-13 PT PT197075955T patent/PT3752516T/pt unknown
- 2019-02-13 ES ES19707595T patent/ES2909616T3/es active Active
- 2019-02-13 RS RS20220372A patent/RS63128B1/sr unknown
- 2019-02-13 JP JP2020564814A patent/JP7296405B2/ja active Active
- 2019-02-13 EP EP19707595.5A patent/EP3752516B1/en active Active
- 2019-02-13 DK DK19707595.5T patent/DK3752516T3/da active
- 2019-02-13 CN CN201980012869.9A patent/CN111902420B/zh active Active
- 2019-02-13 LT LTEPPCT/US2019/017740T patent/LT3752516T/lt unknown
- 2019-02-13 SI SI201930199T patent/SI3752516T1/sl unknown
- 2019-02-13 WO PCT/US2019/017740 patent/WO2019160884A1/en not_active Ceased
- 2019-02-13 KR KR1020207026044A patent/KR102950614B1/ko active Active
- 2019-02-13 TW TW108104810A patent/TW202003539A/zh unknown
- 2019-02-13 PL PL19707595T patent/PL3752516T3/pl unknown
- 2019-02-13 AR ARP190100352A patent/AR114369A1/es not_active Application Discontinuation
- 2019-02-13 HU HUE19707595A patent/HUE058662T2/hu unknown
- 2019-02-13 HR HRP20220520TT patent/HRP20220520T1/hr unknown
- 2019-02-13 SM SM20220168T patent/SMT202200168T1/it unknown
- 2019-11-14 US US16/683,667 patent/US11339185B2/en active Active
-
2022
- 2022-05-05 CY CY20221100320T patent/CY1125159T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102950614B1 (ko) | 2026-04-08 |
| LT3752516T (lt) | 2022-05-10 |
| PT3752516T (pt) | 2022-03-31 |
| DK3752516T3 (da) | 2022-04-11 |
| US20190248828A1 (en) | 2019-08-15 |
| HRP20220520T1 (hr) | 2022-05-27 |
| US10519187B2 (en) | 2019-12-31 |
| RS63128B1 (sr) | 2022-05-31 |
| PL3752516T3 (pl) | 2022-05-02 |
| KR20200120683A (ko) | 2020-10-21 |
| CN111902420B (zh) | 2024-02-02 |
| CN111902420A (zh) | 2020-11-06 |
| JP2021513562A (ja) | 2021-05-27 |
| CY1125159T1 (el) | 2024-12-13 |
| EP3752516B1 (en) | 2022-02-23 |
| HUE058662T2 (hu) | 2022-09-28 |
| JP7296405B2 (ja) | 2023-06-22 |
| US11339185B2 (en) | 2022-05-24 |
| SI3752516T1 (sl) | 2022-05-31 |
| WO2019160884A1 (en) | 2019-08-22 |
| SMT202200168T1 (it) | 2022-05-12 |
| ES2909616T3 (es) | 2022-05-09 |
| AR114369A1 (es) | 2020-08-26 |
| EP3752516A1 (en) | 2020-12-23 |
| US20200079815A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7186764B2 (ja) | 抗癌剤としての環状ジヌクレオチド | |
| US11339185B2 (en) | Cyclic dinucleotides as anticancer agents | |
| KR102651946B1 (ko) | 항암제로서의 시클릭 디뉴클레오티드 | |
| CN111051328B (zh) | 作为抗癌剂的环二核苷酸 | |
| JP7316263B2 (ja) | 抗癌剤としての環状ジヌクレオチド | |
| CN111344297B (zh) | 作为抗癌剂的环二核苷酸 | |
| EP3697801A1 (en) | Cyclic dinucleotides as anticancer agents | |
| CN111801341B (zh) | 作为抗癌剂的环二核苷酸 |